EXEL stock news · Exelixis

Stories about Exelixis (EXEL) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for EXEL

Follow Exelixis (EXEL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 29, 2026, 6:41 PM ET · Results
Exelixis shares what happened in their earnings call for the third quarter of 2026.
Good for EXEL
Exelixis reported strong Q3 sales and profit, led by Cabometyx growth. The results support a brighter business outlook, though sales deductions and unproven future drugs temper the picture.
Oct 20, 2026, 1:46 PM ET · Market
Big investors are making moves with 9 health care stocks today.
Neutral
Exelixis was listed with a call trade labeled bullish. This reports options activity, not a change in the company’s business, so it does not change its outlook.
Sep 11, 2026, 7:12 AM ET · Market
EXELIXIS, INC.: Other Events (EXEL)
Bad for EXEL
The FDA extended Exelixis' NDA review by 3 months to March 3, 2027. This delays possible approval and potential sales, so I read it as unfavorable for Exelixis.